Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization

Räber, Lorenz; Jüni, Peter; Nüesch, Eveline; Kalesan, Bindu; Wenaweser, Peter; Moschovitis, Aris; Khattab, Ahmed A; Bahlo, Maryam; Togni, Mario; Cook, Stéphane; Vogel, Rolf; Seiler, Christian; Meier, Bernhard; Windecker, Stephan (2011). Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. Journal of the American College of Cardiology, 57(21), pp. 2143-2151. New York, N.Y.: Elsevier 10.1016/j.jacc.2011.01.023

Text Räber JAmCollCardiol 2011.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (475kB)

Objectives

This study sought to compare the unrestricted use of everolimus-eluting stents (EES) with sirolimus-eluting stents (SES) in patients undergoing percutaneous coronary intervention.

Background

It is unclear whether there are differences in safety and efficacy between EES and SES during long-term follow-up.

Methods

Using propensity score matching, clinical outcome was compared among 1,342 propensity score–matched pairs of patients treated with EES and SES. The primary outcome was a composite of death, MI, and target vessel revascularization.

Results

The median follow-up was 1.5 years with a maximum of 3 years. The primary outcome occurred in 14.9% of EES- and 18.0% of SES-treated patients up to 3 years (hazard ratio [HR]: 0.83, 95% confidence interval [CI]: 0.68 to 1.00, p = 0.056). All-cause mortality (6.0% vs. 6.5%, HR: 0.92, 95% CI: 0.68 to 1.25, p = 0.59) was similar, risks of myocardial infarction (MI) (3.3% vs. 5.0%, HR: 0.62, 95% CI: 0.42 to 0.92, p = 0.017), and target vessel revascularization (7.0% vs. 9.6%, HR: 0.75, 95% CI: 0.57 to 0.99, p = 0.039) were lower with EES than SES. Definite stent thrombosis (ST) (HR: 0.30, 95% CI: 0.12 to 0.75, p = 0.01) was less frequent among patients treated with EES. The reduced rate of MI with EES was explained in part by the lower risk of definite ST and the corresponding decrease in events associated with ST (HR: 0.25, 95% CI: 0.08 to 0.75, p = 0.013).

Conclusions

The unrestricted use of EES appears to be associated with improved clinical long-term outcome compared with SES. Differences in favor of EES are driven in part by a lower risk of MI associated with ST.

Interest & Impact

Downloads

1 since deposited on 04 Oct 2013
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item